Enfortumab Vedotin as Neoadjuvant Treatment for MIBC

Patients with muscle-invasive bladder cancer (MIBC), who are cisplatin-ineligible, show promising antitumor activity with enfortumab vedotin monotherapy as neoadjuvant treatment. That is the conclusion from a newly published study presented by MD and Professor Daniel Petrylak in this MEDtalk.